DB
QNCX icon

Dmitry Balyasny’s Quince Therapeutics QNCX Stock Holding History

Dmitry Balyasny’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Buy
+69,967
New +$1.61M 0.02% 956
2026
Q1 		– Sell
-139
Closed -$93K – 3410
2025
Q4 		$93K Buy
+139
New +$69.9K ﹤0.01% 2965

Other funds holding QNCX

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dmitry Balyasny's QNCX Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Quince Therapeutics (QNCX) in Q2 2026: 69,967 shares worth $12.6M. The stake represents 0.02% of the portfolio and ranks #956 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in QNCX as recently as Q4 2025.

Dmitry Balyasny first reported a position in QNCX in Q4 2025 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Dmitry Balyasny held 69,967 shares of Quince Therapeutics worth $12.6M as of Q2 2026.
  • Quince Therapeutics was a new Dmitry Balyasny position in Q2 2026.
  • Quince Therapeutics made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #956 holding.
  • Dmitry Balyasny first reported a position in Quince Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.